Trade Mind Medicine (MindMed) Inc. Subordinate Voting Shares - MNMD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.05 |
| Open | 7.08 |
| 1-Year Change | 164.18% |
| Day's Range | 7.08 - 7.63 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | 7.53 | 0.46 | 6.51% | 7.07 | 7.64 | 6.98 |
| Nov 21, 2024 | 7.05 | -0.34 | -4.60% | 7.39 | 7.53 | 6.97 |
| Nov 20, 2024 | 7.50 | 0.36 | 5.04% | 7.14 | 7.67 | 6.99 |
| Nov 19, 2024 | 7.17 | 0.42 | 6.22% | 6.75 | 7.36 | 6.47 |
| Nov 18, 2024 | 6.81 | -0.62 | -8.34% | 7.43 | 7.77 | 6.78 |
| Nov 15, 2024 | 7.66 | -1.32 | -14.70% | 8.98 | 9.79 | 7.66 |
| Nov 14, 2024 | 8.38 | -0.02 | -0.24% | 8.40 | 8.46 | 7.85 |
| Nov 13, 2024 | 8.35 | 0.15 | 1.83% | 8.20 | 8.72 | 8.10 |
| Nov 12, 2024 | 8.16 | -0.35 | -4.11% | 8.51 | 8.68 | 7.98 |
| Nov 11, 2024 | 8.95 | 0.06 | 0.67% | 8.89 | 9.43 | 8.79 |
| Nov 8, 2024 | 8.46 | 0.86 | 11.32% | 7.60 | 9.09 | 7.57 |
| Nov 7, 2024 | 7.46 | 0.56 | 8.12% | 6.90 | 7.99 | 6.90 |
| Nov 6, 2024 | 6.73 | 0.52 | 8.37% | 6.21 | 7.06 | 6.21 |
| Nov 5, 2024 | 6.13 | 0.22 | 3.72% | 5.91 | 6.14 | 5.88 |
| Nov 4, 2024 | 6.03 | 0.03 | 0.50% | 6.00 | 6.16 | 5.86 |
| Nov 1, 2024 | 6.11 | -0.12 | -1.93% | 6.23 | 6.41 | 6.06 |
| Oct 31, 2024 | 6.28 | 0.07 | 1.13% | 6.21 | 6.38 | 6.03 |
| Oct 30, 2024 | 6.33 | 0.02 | 0.32% | 6.31 | 6.61 | 6.28 |
| Oct 29, 2024 | 6.42 | -0.09 | -1.38% | 6.51 | 6.61 | 6.28 |
| Oct 28, 2024 | 6.62 | 0.58 | 9.60% | 6.04 | 6.64 | 6.01 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Mind Medicine (MindMed) Company profile
Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.
Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.
MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.
The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.
In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.
MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.
MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.
| Industry: | Biotechnology & Medical Research (NEC) |
One World Trade Center
Suite 8500
NEW YORK
NEW YORK 10007
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com